Project Details
| Short title | R3767-ONC-2235 |
|---|---|
| Acronym | R3767-ONC-2235 |
| Status | Active |
| Effective start/end date | 18/09/23 → 25/05/28 |
CTU: A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Contacos, Christine (Clinical Trial Unit Staff)
- Keshiya, Shikara (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research